Current options for anti-aggregation treatment for the prevention of atherosclerotic complications in diabetic patients

1.Albertini JP, Valensi P, Lormeau B et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM: effect of intensive insulin treatment. Diabetes Care 1998; 21: 1008–1013.

2.American Diabetes Association. Aspirin Therapy in Diabetes. Diabetes Care 2004; 27(Suppl): 72-73.

3.Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Influence of Aspirin Resistance on Platelet Function Profiles in Patients on Long-Term Aspirin and Clopidogrel After Percutaneous Coronary Intervention. Am J Cardiol 2006; 97: 38-43.

4.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

5.Aso Y, Matsutomo N, Wakabayashi S et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflamatory state and impairement of fibrinolysis in patiens with type 2 diabetes. Diabetes Care 2005; 28: 2211-2216.

6.Bartnik M, Rydén L, Ferrari R et al on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004; 25: 1880-1890.

7.Basu S, Larsson A, Vessby J et al. Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation. Diabetes Care 2005; 28: 1371-1375.

8.Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166–2179.

9.Brown LC, Johnson JA, Majumdar SR et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171: 1189-1192.

10.Ceriello A, Motz E. Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy? (Comment). Diabetologia 1996; 39: 1405–1406.

11.Davi G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Eng J Med 1990; 322: 1769-1774.

12.Davi G, Ciabattoni G, Consoli A et al. In vivo formation of 8-iso-PGF2 and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.

13.Dibra A, Kastrati A, Mehilli J et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670.

14.Dormandy JA et al. The PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289.

15.Festa A et al. Elevated levels of acute phase proteins and plasminogen activator inhibitor – 1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis study. Diabetes 2002; 51: 1131-1137.

16.Final report on the aspirin component of the ongoing Physicians’ Health Study Research Group. N Engl J Med 1989; 321:129-135.

17.Friend M, Vucenik I, Miller M. Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326: 82–83.

18.Gresele P, Guglielmini G, De Angelis M et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. JACC 2003; 41: 1013-1020.

19.Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105: 1620–1622.

20.Harpaz D, Gottlieb S, Graff E et al. Effects of aspirin treatment on survival in non-insulin - dependent diabetic patients with coronary artery disease. Am Heart J 1998; 105: 484-487.

21.Helmersson J, Vessby B, Larsson A et al. Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population. Circulation 2004; 109: 1729-1734.

22.Hirsh J, Bhatt DL. Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations: Lessons From the CAPRIE and CURE Studies. Arch Intern Med 2004; 164: 2106-2110.

23.Jiménez-Quevedo P, Sabaté M, Angiolillo D et al. LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. Eur Heart J 2005; 26: 2307-2312.

24.Lev EI, Patel RT, Maresh KJ et al. Aspirin and Clopidogrel Drug response in patients Undergoing Percutaneous Cornary Intervention: The Role of Dual Drug Rezistence. JACC 2006; 47: 27-33.

25.Neri Serneri GG, Coccheri S, Marubini E et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-1852.

26.Malý J, Malá H, Pecka M et al. Změny hemostázy u obézních při redukci hmotnosti. Vnitř Lék 2001; 47: 203-209.

27.Malik S, Wong ND, Franklin S et al. Cardiovascular Disease in U.S. Patients With Metabolic Syndrome, Diabetes, and Elevated C-Reactive Protein. Diabetes Care 2005; 28: 690-693.

28.Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–17.

29.Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. JACC 2004; 44: 2293 -2300.

30.Moses JW et al. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. N Eng J Med 2003; 349: 1315-1323.

31.Olexa P, Olexová M. Inhibitor aktivátoru plasminogenu (PAI-1), ischemická choroba srdce a diabetes mellitus. Vnitř Lék 2003; 49: 222-226.

32.Wallentin L, Wolcox RG, Weaver WD. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-797.

33.Pfutzner A, Marx N, Lübben G et al. Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control. JACC 2005; 45: 1925-1931.

34.Sacco M, Tognoni G, Pellegrinni F, Nicolucci A et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetes patiens. Diabetes Care 2003; 26: 3264-3272.

35.Serebruany VL, Pokov AN, Malinin AI et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J 2006; 151: 92-99.

36.Shechter MCN, Bairey Merz MJ et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 300-307.

37.Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor γ agonist rosiglitazon reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: 1-6.

38.Staško J, Hudeček J, Kubisz P. Trombínom aktivovatelný inhibitor fibrinoolýzy (TAFI) a jeho význam v regulaci fibrinolýzy. Vnitř Lék 2004; 50: 36-44.

39.Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129-135.

40.Špác J, Pařenica J. Aspirínový paradox je méně vyjádřen u diabetiků s akutním koronárním syndromem než u nediabetiků. Přednáška XII. výročního kongresu české internistické společnosti ČLS J. E. Purkyně. Vnitř Lék 2005; 51: 1186.

41.Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-654.

42.The ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report. JAMA 1992; 268: 1292-1300.